Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Virus Diseases | 3 | 2024 | 280 | 1.290 |
Why?
|
| Antigens, Neoplasm | 4 | 2021 | 386 | 1.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2024 | 164 | 1.080 |
Why?
|
| BK Virus | 2 | 2024 | 60 | 1.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 1201 | 1.020 |
Why?
|
| T-Lymphocytes | 6 | 2025 | 1727 | 0.890 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 294 | 0.840 |
Why?
|
| Salvage Therapy | 2 | 2021 | 192 | 0.800 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 293 | 0.760 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 206 | 0.700 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 344 | 0.650 |
Why?
|
| Multiple Myeloma | 2 | 2020 | 170 | 0.640 |
Why?
|
| Lymphoma | 1 | 2021 | 322 | 0.570 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 504 | 0.510 |
Why?
|
| Monocytes | 1 | 2017 | 345 | 0.480 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2024 | 397 | 0.480 |
Why?
|
| Dendritic Cells | 1 | 2017 | 414 | 0.460 |
Why?
|
| Adenoviridae | 2 | 2024 | 604 | 0.370 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2024 | 472 | 0.300 |
Why?
|
| Transplant Recipients | 3 | 2024 | 217 | 0.290 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 539 | 0.270 |
Why?
|
| Transplantation, Homologous | 2 | 2024 | 666 | 0.240 |
Why?
|
| Immunological Synapses | 1 | 2025 | 26 | 0.230 |
Why?
|
| Humans | 19 | 2025 | 125086 | 0.230 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 61 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 104 | 0.220 |
Why?
|
| Graft vs Host Disease | 3 | 2024 | 542 | 0.220 |
Why?
|
| Oncolytic Virotherapy | 1 | 2024 | 85 | 0.220 |
Why?
|
| Viremia | 1 | 2024 | 128 | 0.210 |
Why?
|
| Polyomavirus Infections | 1 | 2024 | 90 | 0.210 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 676 | 0.210 |
Why?
|
| Immunity, Cellular | 1 | 2023 | 206 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2024 | 679 | 0.190 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 264 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2023 | 410 | 0.190 |
Why?
|
| Microdialysis | 1 | 2021 | 57 | 0.180 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 30 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 57 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 829 | 0.180 |
Why?
|
| Electrocorticography | 1 | 2021 | 69 | 0.170 |
Why?
|
| Electrodes, Implanted | 1 | 2021 | 168 | 0.170 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 140 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 243 | 0.160 |
Why?
|
| Leukemia | 1 | 2022 | 371 | 0.150 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 642 | 0.150 |
Why?
|
| Breathing Exercises | 1 | 2018 | 7 | 0.150 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2021 | 206 | 0.150 |
Why?
|
| Airway Resistance | 1 | 2018 | 36 | 0.150 |
Why?
|
| Adult | 8 | 2024 | 29632 | 0.150 |
Why?
|
| Vaccination | 1 | 2023 | 961 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2023 | 752 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 269 | 0.140 |
Why?
|
| Respiration | 1 | 2018 | 119 | 0.140 |
Why?
|
| Aged | 5 | 2024 | 19861 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 1155 | 0.140 |
Why?
|
| Phenotype | 2 | 2024 | 4260 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 198 | 0.130 |
Why?
|
| Middle Aged | 5 | 2024 | 26926 | 0.120 |
Why?
|
| Antioxidants | 1 | 2018 | 369 | 0.120 |
Why?
|
| Biomarkers | 3 | 2021 | 3081 | 0.120 |
Why?
|
| Recurrence | 3 | 2024 | 1421 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1275 | 0.110 |
Why?
|
| Young Adult | 3 | 2021 | 9052 | 0.100 |
Why?
|
| Exercise | 1 | 2018 | 812 | 0.100 |
Why?
|
| Cytokines | 1 | 2017 | 1288 | 0.090 |
Why?
|
| Male | 7 | 2024 | 61463 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3052 | 0.090 |
Why?
|
| Prognosis | 1 | 2021 | 4638 | 0.090 |
Why?
|
| Female | 7 | 2024 | 66747 | 0.090 |
Why?
|
| Apoptosis | 1 | 2017 | 1805 | 0.090 |
Why?
|
| Lung | 1 | 2018 | 1497 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 2792 | 0.080 |
Why?
|
| Brain | 1 | 2021 | 2999 | 0.080 |
Why?
|
| Adolescent | 3 | 2021 | 19351 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 3349 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6597 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.060 |
Why?
|
| CD28 Antigens | 1 | 2025 | 81 | 0.060 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 73 | 0.060 |
Why?
|
| Tumor Virus Infections | 1 | 2024 | 135 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2024 | 325 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 888 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 58 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 191 | 0.040 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1638 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2018 | 26 | 0.040 |
Why?
|
| Malondialdehyde | 1 | 2018 | 61 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 77 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 119 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 494 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2018 | 91 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2018 | 59 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1241 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 330 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 483 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 794 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1398 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1143 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1254 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 4531 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6327 | 0.020 |
Why?
|
| Child | 2 | 2022 | 24384 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 12391 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 17632 | 0.020 |
Why?
|
| Animals | 1 | 2024 | 34218 | 0.010 |
Why?
|